Eli Lilly has begun construction on a $6.5 billion pharmaceutical manufacturing facility in Houston’s Generation Park. The project will occupy 236 acres and include at least six buildings totaling about 808,000 square feet, making it a major addition to the city’s industrial development pipeline.
Key Takeaways
- Eli Lilly has broken ground on a $6.5 billion manufacturing facility in northeast Houston.
- The project is planned for 236 acres within Generation Park.
- The development is expected to include at least six buildings totaling approximately 808,000 square feet.
- Construction is expected to continue into 2027.
- The facility is planned to manufacture active pharmaceutical ingredients.
Eli Lilly Begins Construction on the Houston Facility
Eli Lilly has started construction of a $6.5 billion pharmaceutical manufacturing facility in northeast Houston, establishing a major new building project within Generation Park. The facility is planned as a manufacturing site for active pharmaceutical ingredients.
The project covers 236 acres and is expected to include at least six buildings. Together, those buildings are planned to provide approximately 808,000 square feet of space.
The size of the development places the project among the large industrial building projects currently being developed in the Houston area. Its scale is defined by both the land involved and the amount of planned building space.
Houston’s industrial construction pipeline also includes warehouse developments. For example, a 714,000-square-foot industrial campus is planned in North Houston, with three warehouse facilities scheduled for completion in 2027.
The Houston manufacturing project is part of Eli Lilly’s plans for pharmaceutical production. The planned facility will provide space specifically for manufacturing active pharmaceutical ingredients rather than serving as a general commercial or residential development.
Construction is expected to continue into 2027. The multiyear schedule reflects the scale of the planned buildings and the amount of site development required for the facility.
$6.5 Billion Project Covers 236 Acres in Generation Park
The Houston facility will occupy 236 acres within Generation Park, a large development area in northeast Houston. The land area provides the site for the planned manufacturing buildings and associated development.
The $6.5 billion project combines a substantial land footprint with a large construction budget. Eli Lilly’s planned investment is tied to the development of the pharmaceutical manufacturing facility and its associated buildings.
At least six buildings are planned for the site. The buildings are expected to collectively contain about 808,000 square feet.
The project therefore involves more than a single industrial structure. Its planned layout includes multiple buildings within the 236-acre site, creating a large-scale manufacturing complex.
The location in northeast Houston also places the facility within the city’s established development framework. Generation Park is the designated location for the project.
The project is classified as pharmaceutical manufacturing construction, giving the buildings a specialized industrial purpose. The planned use distinguishes the development from warehouses, office buildings, retail properties and other conventional commercial construction.
Six Buildings Will Provide About 808,000 Square Feet
The planned development includes at least six buildings with a combined area of approximately 808,000 square feet. That amount of building space gives the project a substantial physical footprint within Generation Park.
The confirmed plan calls for at least six buildings as part of the pharmaceutical manufacturing facility.
The total square footage provides a measure of the construction scale. At approximately 808,000 square feet, the project requires a large building program across a 236-acre site.
The development’s building count and total floor area also distinguish it from smaller manufacturing projects. Instead of a single facility, Eli Lilly is developing a group of buildings as part of one manufacturing site.
The construction schedule extends into 2027. The planned timeline gives the project multiple stages of building activity before the facility is completed.
Construction costs are also a consideration for U.S. commercial development. Recent data showed that U.S. construction costs are rising, with nonresidential construction inputs up 8.9% year over year in August.
The combination of six or more buildings, approximately 808,000 square feet and 236 acres defines the physical scope of the Houston development.
Facility Will Manufacture Pharmaceutical Ingredients
The planned Houston facility will manufacture active pharmaceutical ingredients. Those ingredients are used in pharmaceutical production, giving the project a specialized manufacturing purpose.
Eli Lilly is developing the facility specifically for pharmaceutical manufacturing rather than for general industrial occupancy. The intended use therefore determines the type of buildings being constructed and the purpose of the site.
The planned manufacturing function is tied directly to the project’s $6.5 billion investment. The development includes the buildings and site required for the pharmaceutical manufacturing operation.
The facility’s planned use also establishes the project as an industrial real estate development. The site is not being developed as residential property, office space or retail space.
The approximately 808,000 square feet of planned buildings will form the physical facilities for the manufacturing operation. The 236-acre site provides the land for the overall development.
Construction Continues Through 2027
Construction of the Houston facility is expected to continue into 2027. The timeline places the project beyond a single construction season and into the following year.
The development’s scale includes 236 acres, at least six buildings and approximately 808,000 square feet of planned building space. Those elements define the construction program that Eli Lilly is undertaking in Generation Park.
The $6.5 billion investment is associated with the manufacturing facility and its development. The project therefore combines a large construction budget with a substantial building footprint.
The completed development is planned to serve pharmaceutical manufacturing operations. Its purpose will be the production of active pharmaceutical ingredients at the Houston site.
For Houston’s industrial property market, the project adds a large specialized manufacturing development to the city’s building pipeline. Its confirmed project details center on the site’s acreage, building count, planned square footage, investment and construction timeline.
Frequently Asked Questions
How much is Eli Lilly’s Houston manufacturing facility worth?
Eli Lilly’s Houston manufacturing facility is part of a $6.5 billion project. The investment covers the development of the pharmaceutical manufacturing facility in Generation Park.
Where is Eli Lilly building its Houston manufacturing facility?
Eli Lilly is building the facility in Generation Park in northeast Houston. The project is planned across 236 acres.
How large will the Houston Eli Lilly facility be?
The development is expected to include at least six buildings totaling approximately 808,000 square feet. The buildings will form the planned pharmaceutical manufacturing facility.
What will Eli Lilly manufacture at the Houston facility?
The facility is planned to manufacture active pharmaceutical ingredients. The project is specifically intended for pharmaceutical manufacturing.
When is construction of the Houston facility expected to continue through?
Construction is expected to continue into 2027. The project is being developed on a 236-acre site in Generation Park.
